Expression of oestrogen receptors, ERalpha, ERbeta, and ERbeta variants, in endometrial cancers and evidence that prostaglandin F may play a role in regulating expression of ERalpha

Frances Collins, Sheila MacPherson, Pamela Brown, Vincent Bombail, Alistair R W Williams, Richard A Anderson, Henry N Jabbour, Philippa T K Saunders

Research output: Contribution to journalArticlepeer-review

Abstract

Endometrial cancer is the most common gynaecological malignancy; risk factors include exposure to oestrogens and high body mass index. Expression of enzymes involved in biosynthesis of oestrogens and prostaglandins (PG) is often higher in endometrial cancers when compared with levels detected in normal endometrium. Oestrogens bind one of two receptors (ERalpha and ERbeta) encoded by separate genes. The full-length receptors function as ligand-activated transcription factors; splice variant isoforms of ERbeta lacking a ligand-binding domain have also been described. PGs act in an autocrine or paracrine manner by binding to specific G-protein coupled receptors.
Original languageEnglish
Pages (from-to)330
JournalBMC Cancer
Volume9
DOIs
Publication statusPublished - 2009

Fingerprint

Dive into the research topics of 'Expression of oestrogen receptors, ERalpha, ERbeta, and ERbeta variants, in endometrial cancers and evidence that prostaglandin F may play a role in regulating expression of ERalpha'. Together they form a unique fingerprint.

Cite this